Examkin

Question

Difficulty: Very hardPulmonary and Critical Care

A 34-year-old woman with no significant past medical history is evaluated in the clinic for a 6-month history of progressively worsening exertional dyspnea and fatigue. She has no cough, wheezing, orthopnea, or leg swelling. She does not smoke. Vital signs are within normal limits. Physical examination reveals a prominent right ventricular heave, a loud pulmonic component of the second heart sound (P2), and a faint holosystolic murmur at the left lower sternal border that increases in intensity with inspiration. The lungs are clear to auscultation bilaterally. Electrocardiogram shows right axis deviation and right ventricular hypertrophy. Suspecting a primary pulmonary vascular disorder, the physician plans a comprehensive diagnostic workup.

Arrange the following diagnostic and management steps in the correct chronological sequence according to consensus guidelines for unexplained pulmonary hypertension, moving from initial screening to definitive management:

  1. 1Perform transthoracic echocardiography to estimate pulmonary artery pressures and assess right ventricular function.
  2. 2Obtain a radionuclide ventilation/perfusion (V/Q) scan to screen for chronic thromboembolic pulmonary hypertension.
  3. 3Perform right heart catheterization to directly measure pulmonary hemodynamics and confirm precapillary physiology.
  4. 4Administer inhaled nitric oxide to assess for acute pulmonary vasoreactivity.
  5. 5Initiate targeted pulmonary vasodilator therapy based on hemodynamic and vasoreactivity results.

Answer

The correct sequence is: Echocardiography, followed by a V/Q scan, then right heart catheterization, followed by acute vasoreactivity testing during the catheterization, and finally initiation of targeted pulmonary vasodilator therapy.
The correct sequence for evaluating unexplained pulmonary hypertension begins with non-invasive screening using transthoracic echocardiography to estimate pulmonary pressures. Once PH is suspected, a V/Q scan must be performed to evaluate for chronic thromboembolic pulmonary hypertension (CTEPH), as it is highly sensitive for chronic clots. If the V/Q scan is normal or low probability, right heart catheterization is strictly required to definitively confirm precapillary hemodynamics (mean pulmonary artery pressure ≥ 20 mmHg, PCWP ≤ 15 mmHg, PVR ≥ 3 Wood units). During the catheterization for idiopathic PAH, acute vasoreactivity testing with a short-acting vasodilator (like inhaled nitric oxide) is performed. Finally, based on the hemodynamic and vasoreactivity results, targeted PAH therapy (such as a calcium channel blocker for vasoreactive patients, or an endothelin receptor antagonist for non-reactive patients) is initiated.

Step-by-Step Solution

1
Identify the most likely diagnosis and the best initial screening test.
The patient's presentation strongly suggests idiopathic pulmonary arterial hypertension. Transthoracic echocardiography is selected as the first step.
Echocardiography is the universal non-invasive standard to estimate right ventricular systolic pressure and evaluate for left-sided heart disease.
2
Determine the appropriate non-invasive test to rule out Group 4 pulmonary hypertension.
A ventilation/perfusion (V/Q) scan is ordered next.
Guidelines mandate V/Q scanning to screen for chronic thromboembolic pulmonary hypertension (CTEPH) before invasive testing, as it is significantly more sensitive than CT pulmonary angiography for chronic microvascular clots.
3
Select the definitive diagnostic test to confirm precapillary hemodynamics.
Right heart catheterization (RHC) is performed.
RHC is the gold standard required to definitively differentiate pre-capillary PAH from post-capillary venous hypertension and to formally establish the diagnosis.
4
Determine the appropriate procedural test to guide specific medical therapy.
Acute vasoreactivity testing with inhaled nitric oxide is conducted.
During RHC, vasoreactivity must be assessed in idiopathic PAH to identify the small subset of patients who will respond favorably to high-dose calcium channel blockers.
5
Choose the final management step based on the comprehensive diagnostic workup.
Targeted pulmonary vasodilator therapy is initiated.
Once formal hemodynamics and vasoreactivity status are established, appropriate evidence-based therapy can be safely prescribed without risk of exacerbating unconfirmed underlying conditions.

Key Concept

The diagnostic algorithm for pulmonary hypertension requires sequential non-invasive screening (Echocardiography, then V/Q scan) followed by invasive confirmation (Right heart catheterization with vasoreactivity testing) before initiating targeted PAH therapy.
Estimated Time:2m 30s
Rate this question

Topics

Pulmonary and Critical Care

More questions from this topic